Treatment Intervention Advisory Committee Review and Determination

Date: October, 2016

To: DHS/DLTC

From: Wisconsin Department of Health Services Autism and other Developmental Disabilities
Treatment Intervention Advisory Committee: Lana Collet-Klingenberg, Ph.D. (chairperson)

RE: Determination of DIR Floortime as a proven and effective treatment for individuals with autism spectrum disorder and/or other developmental disabilities

☐ This is an initial review
☒ This is a re-review. The initial review was 11-21-2013. Additional reviews occurred on 7-25-2014 and 6-21-2015

Section One: Overview and Determination

Please find below a statement of our determination as to whether or not the committee views DIR Floortime as a proven and effective treatment for children with autism spectrum disorder and/or other developmental disabilities. In subsequent sections you will find documentation of our review process including a description of the proposed treatment, a synopsis of review findings, the treatment review evidence checklist, and a listing of the literature considered. In reviewing treatments presented to us by DHS/DLTC, we implement a review process that carefully and fully considers all available information regarding a proposed treatment. Our determination is limited to a statement regarding how established a practice is in regard to quality research. We do not make funding decisions.

Description of proposed treatment
According to the DIR/Floortime website, the DIR (Developmental, Individual Difference, Relationship-based) Model and the DIR/Floortime Approach is a framework that helps clinicians, parents and educators conduct a comprehensive assessment and develop an intervention program tailored to the unique challenges of children with Autism Spectrum Disorders (ASD) and other developmental challenges. The DIR/Floortime model emphasizes the critical role of parents and other family members because of the importance of their emotional relationships with the child.

Synopsis of review
In the case of DIR/Floortime, please refer to the attached reference listing that details the reviewed research. The committee’s conclusions regarding DIR/Floortime include the following:

DIR/Floortime was initially reviewed in November, 2013. At that time three DIR/Floortime specific scientific studies related to the effectiveness of DIR/Floortime as a unique comprehensive package in peer-reviewed journals were reviewed. Authoritative bodies had not identified DIR/Floortime as a specific practice in their reports. DIR/Floortime was identified with a Level 4 rating: Insufficient Evidence at that time.
DIR/Floortime was reviewed again in July, 2014. No additional empirical evidence on DIR/Floortime was found. DIR/Floortime was reviewed again in June, 2015. No additional empirical evidence on DIR/Floortime was found.

There was a peer reviewed study published in 2016, however, the study examined the reflective functioning capacities of caregivers, rather than individuals with autism or other developmental disabilities.

In sum, it is the decision of the committee that DIR/Floortime remain at a Level 4- Insufficient Evidence- Experimental Treatment.
Section Two: Rationale for Focus on Research Specific to Comprehensive Treatment Packages (CTP) or Models

In the professional literature, there are two classifications of interventions for individuals with Autism Spectrum Disorder (National Research Council, 2001; Odom et al., 2003; Rogers & Vismara, 2008):

(a) **Focused intervention techniques** are individual practices or strategies (such as positive reinforcement) designed to produce a specific behavioral or developmental outcome, and

(b) **Comprehensive treatment models** are “packages” or programs that consist of a set of practices or multiple techniques designed to achieve a broader learning or developmental impact.

To determine whether a treatment package is proven and effective, the Treatment Intervention Advisory Committee (TIAC) will adopt the following perspective as recommended by Odom et al. (2010):

The individual, focused intervention techniques that make up a comprehensive treatment model may be evidence-based. The research supporting the effectiveness of separate, individual components, however, does not constitute an evaluation of the comprehensive treatment model or “package.” The TIAC will consider and review only research that has evaluated the efficacy of implementing the comprehensive treatment as a package. Such packages are most often identifiable in the literature by a consistently used name or label.


Section Three: DLTC-TIAC Treatment Review Evidence Checklist

Name of Treatment: Insert therapy name

*Level 1 - Well Established or Strong Evidence (DHS 107 - Proven & Effective Treatment)*

- Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, National Professional Development Center) have approved of or rated the treatment package as having a strong evidence base; authorities are in agreement about the level of evidence.
- There exist ample high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
  - Minimum of two group studies or five single subject studies or a combination of the two.
  - Studies were conducted across at least two independent research groups.
  - Studies were published in peer reviewed journals.
- There is a published procedures manual for the treatment, or treatment implementation is clearly defined (i.e., replicable) within the studies.
- Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

*Notes:* At this level, include ages of participants and disabilities identified in body of research

*Level 2 – Established or Moderate Evidence (DHS 107 - Proven & Effective Treatment)*

- Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have approved of or rated the treatment package as having at least a minimal evidence base; authorities may not be in agreement about the level of evidence.
- There exist at least two high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
  - Minimum of one group study or two single subject studies or a combination of the two.
  - Studies were conducted by someone other than the creator/provider of the treatment.
  - Studies were published in peer reviewed journals.
- Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

*Notes:* At this level, include ages of participants and disabilities identified in body of research
Level 3 – Emerging Evidence (DHS 107 – Promising as a Proven & Effective Treatment)

☑ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have recognized the treatment package as having an emerging evidence base; authorities may not be in agreement about the level of evidence.

☐ There exists at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.

☑ May be one group study or single subject study.

☑ Study was conducted by someone other than the creator/provider of the treatment.

☐ Study was published in peer reviewed journal.

☑ Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research

Level 4 – Insufficient Evidence (Experimental Treatment)

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.

☒ There is not at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.

☑ Study was conducted by the creator/provider of the treatment.

☑ Study was not published in a peer reviewed journal.

☒ Participants (i.e., N) are not clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes:
Level 5 – Untested (Experimental Treatment) &/or Potentially Harmful

☑ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.

☑ There are no published studies supporting the proposed treatment package.

☐ There exists evidence that the treatment package is potentially harmful.
  ☐ Authoritative bodies have expressed concern regarding safety/outcomes.
  ☐ Professional bodies (i.e., organizations or certifying bodies) have created statements regarding safety/outcomes.

Notes: At this level, please specify if the treatment is reported to be potentially harmful, providing documentation

Date: October 28, 2016

Committee Members Completing Initial Review of Research Base: Shannon Stuart, Amy Van Hecke

Committee Decision on Level of Evidence to Suggest the Proposed Treatment is Proven and Effective: Level 4- Insufficient Evidence- Experimental Treatment

References Supporting Identification of Evidence Levels:


Section Four: Literature Review

June 2016 review:


Literature Reviewed for Previous Determinations:

